AstraZeneca

For #Investors and #Media Today we announced an agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies. We believe EsoBiotec’s world-leading in vivo cell therapy platform has the potential to transform cell therapy, increasing the number of patients that may be able to access and benefit from these innovative treatments. Traditional cell therapies require cells be removed from a patient, genetically modified outside of the body, and then readministered to the patient as a medicine after immune cell depletion, a process that typically takes weeks. In vivo cell therapy enables administration of cell therapies in minutes, through a simple IV injection and without the need for immune cell depletion. By engineering immune cells directly within the patient’s body, the platform offers a promising approach to streamline processes, reducing complexities and manufacturing timelines, while increasing patient access. #AstraZenecaBusinessNews

Every patient deserves a timely diagnosis. Transthyretin-mediated amyloidosis (ATTR) is a complex, often undetected condition that can be life threatening if left untreated. At AstraZeneca, we’re advancing cutting edge science to improve early detection, raise awareness and drive meaningful change for patients living with ATTR. Discover how we’re making a difference: https://learn.az/60470BoUc

Our CEO Pascal Soriot joined His Majesty King Charles III, global CEOs and world leaders at the Sustainable Markets Initiative 2025 Terra Carta Roundtables & Exhibition. Investing in a sustainable transition is vital to unlock long-term economic growth, drive resilience across markets and improve the health of people, society and the planet. Learn about the collective impact of the SMI Health Systems Task Force, which Pascal chairs, here: https://learn.az/60410RUXD #SMITerraCarta

Chronic kidney disease (CKD) silently affects millions worldwide, often going undiagnosed until it’s too late. Targeted screening policies can change that. As we mark 20 years of #WorldKidneyDay, the need for action has never been more urgent, as the clinical, socioeconomic, and environmental burden of CKD continues to rise. It’s time to act now. Learn more and help shape the future of kidney health: https://learn.az/6041LjhNb #KidneyHealthMatters #ForKidneyHealth

We follow the science to unlock the future of novel therapies that target the root cause of disease. Genomics has helped us uncover much about human health, but it only tells part of the story. Multiomics is unlocking deeper insights, transforming how we detect, understand and treat chronic diseases. Discover how this approach is shaping the future of medicine: https://learn.az/60440GPGq #WhatScienceCanDo

Our CFO, Aradhana Sarin, recently hosted research psychologist and award-winning professor, Alison Fragale, on her podcast “In Conversation with…”. This must-watch episode offers science-based strategies for women to confidently advocate for themselves. Discover how you can use these universal tools to negotiate, influence, and lead effectively: https://learn.az/604201omE #WhatScienceCanDo #LeadershipDevelopment

Are you a young leader dedicated to advancing health equity and building a healthier future? Apply to the Young Health Programme (YHP) Impact Fellowship in partnership with One Young World to be part of a global health community: https://learn.az/60420D9aa #YoungHealthProgramme #OYW25

This International Women's Day, join us in celebrating the remarkable impact of women in healthcare. Our CFO, Aradhana Sarin, recently spoke with two inspiring alumni from our Young Health Programme Impact Fellowship. These extraordinary women shared their journeys developing innovative digital healthcare solutions to advance health equity in underserved communities, with a particular focus on empowering women in India and Tanzania. Discover how their work is driving meaningful change to create a healthier future for all: https://learn.az/6044L4eNp #IWD2025 #YoungHealthProgramme #ForAllWomenAndGirls

We are honoured to be recognized by the FTSE Women Leaders Review as a top performer in the FTSE 100 and FTSE 350 for our representation of women, and to be named one of Forbes Top Companies for Women. As we approach #IWD2025, these accolades highlight our commitment to a culture of inclusion, where our teams reflects the diversity of the communities we serve. #FTSEWomenLeaders #TopCompaniesForWomen

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex respiratory disease that causes soft tissue growths in the nasal passages, which may require repeat surgeries and long-term oral corticosteroids. By deepening our understanding of the critical role the epithelium plays in respiratory diseases we can drive meaningful progress towards better, more effective treatments for patients. Learn more about the latest research shaping the future of respiratory care: https://learn.az/6042LsZug